Literature DB >> 34472689

Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment.

Huilin Tang1, Stephen E Kimmel2, Inmaculada Hernandez3, Maria M Brooks4, Kenneth Cusi5, Steven M Smith1,6, Weilong Shi7, Almut G Winterstein1,2,6, Jared W Magnani8, Jingchuan Guo1,6.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34472689     DOI: 10.1111/dom.14540

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


× No keyword cloud information.
  1 in total

1.  Newer glucose-lowering drugs and risk of dementia: A meta-analysis of cardiovascular outcome trials.

Authors:  Huilin Tang; Shu Niu; Joshua Brown; Jingkai Wei; Hui Shao; Jiang Bian; Jingchuan Guo
Journal:  J Am Geriatr Soc       Date:  2022-05-25       Impact factor: 7.538

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.